clinical trial · NCT04349280
A Study to Evaluate the Efficacy and Safety of Bintrafusp Alfa (M7824) Monotherapy in Metastatic or Locally Advanced Urothelial Cancer
GlaxoSmithKline·phase1·terminated·n = 25
NeoplasmsBintrafusp alfa
brief summary
The purpose of this study is to evaluate bintrafusp alfa in participants with metastatic or locally advanced urothelial cancer. This trial provides the first evaluation of bintrafusp alfa in participants with urothelial cancer that has progressed following platinum therapy.
started
Oct 15, 2020
primary completion
Aug 15, 2022
completion
Aug 15, 2022
last updated
Apr 18, 2024
official title
A Phase Ib Trial to Evaluate the Efficacy and Safety of Bintrafusp Alfa Monotherapy in Metastatic or Locally Advanced/Unresectable Urothelial Cancer With Disease Progression or Recurrence Following Treatment With a Platinum Agent
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol